Novo Nordisk ADR (NVO) concluded trading on Wednesday at a closing price of $111.69, with 6.54 million shares of worth about $730.12 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -22.04% during that period and on December 11, 2024 the price saw a gain of about 2.29%. Currently the company’s common shares owned by public are about 3.34B shares, out of which, 3.34B shares are available for trading.
Stock saw a price change of 2.50% in past 5 days and over the past one month there was a price change of 2.38%. Year-to-date (YTD), NVO shares are showing a performance of 7.97% which increased to 15.56% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $94.73 but also hit the highest price of $148.15 during that period. The average intraday trading volume for Novo Nordisk ADR shares is 5.12 million. The stock is currently trading 4.81% above its 20-day simple moving average (SMA20), while that difference is up 0.55% for SMA50 and it goes to -12.06% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novo Nordisk ADR (NYSE: NVO) currently have 3.34B outstanding shares and institutions hold larger chunk of about 10.00% of that.
The stock has a current market capitalization of $372.87B and its 3Y-monthly beta is at 0.40. PE ratio of stock for trailing 12 months is 36.22, while it has posted earnings per share of $3.08 in the same period. Its PEG reads 3.29 and has Quick Ratio of 0.75 while making debt-to-equity ratio of 0.47. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NVO, volatility over the week remained 1.77% while standing at 1.75% over the month.
Stock’s fiscal year EPS is expected to rise by 20.09% while it is estimated to increase by 24.40% in next year. EPS is likely to shrink at an annualized rate of 11.00% for next 5-years, compared to annual growth of 16.48% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on May 30, 2024 offering a Buy rating for the stock and assigned a target price of $156 to it. Coverage by BMO Capital Markets stated Novo Nordisk ADR (NVO) stock as an Outperform in their note to investors on April 12, 2024, suggesting a price target of $163 for the stock. Stock get an Overweight rating from Cantor Fitzgerald on December 01, 2023.
